← Human Trials & Peer-Reviewed Studies
Acoustic cardiography S3 detection use in problematic subgroups and B-type natriuretic peptide "gray zone": secondary results from the Heart failure and Audicor technology for Rapid Diagnosis and Initial Treatment Multinational Investigation
Plain-language guide to PMID 20627217 (2011): clinical trial study of BNP (Nesiritide).
Key Facts
- PMID
- 20627217
- Journal
- The American journal of emergency medicine
- Year
- 2011
- Study type
- Clinical Trial
- Authors
- Maisel AS et al. (11 authors)
- DOI
- 10.1016/j.ajem.2010.03.032
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at BNP (Nesiritide).
Their goal in this secondary analysis was to determine if the strength of the S3 can provide diagnostic/prognostic information in problematic heart failure subgroups.
This secondary analysis of subgroups from the HEARD-IT database used univariate/multivariate regression to determine the diagnostic/prognostic ability of the S3 strength.
Why It Was Studied
Dyspneic emergency department (ED) patients present a diagnostic dilemma.
The HEart failure and Audicor technology for Rapid Diagnosis and Initial Treatment (HEARD-IT) multinational trial evaluated the S3 via acoustic cardiography (Audicor).
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.
Dyspneic ED patients older than 40 years and not on dialysis were prospectively enrolled.
How the Study Was Run
A gold standard AHF diagnosis was determined by 2 cardiologists blinded to acoustic cardiography results.
The S3 strength parameter was delineated on a scale of 0 to 10.
What Was Measured
The HEart failure and Audicor technology for Rapid Diagnosis and Initial Treatment (HEARD-IT) multinational trial evaluated the S3 via acoustic cardiography (Audicor).
The subject headings attached to it are Acute Disease, Body Mass Index, Dyspnea, Electrocardiography, Emergency Service, Hospital, Heart Auscultation and Heart Failure.
What This Means in Plain Language
This is a clinical trial of BNP (Nesiritide).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2011 (The American journal of emergency medicine), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.